

Dr. Manfred E. Wolff, Ph.D., FAAPS
President & CEO, Intellepharm, Inc.

Intellepharm, Inc.
1304 Morningside Drive
Laguna Beach, CA 92651-2809
Phone: 949-494-5458 or (mobile) 949-510-6339
Fax: call



EXPERT WITNESS SERVICES

As President of Intellepharm, Inc., Dr. Wolff has provided expert witness testimony in the US, UK, and Canada during the past 18 years. The litigation involved includes pharmaceutical patent validity and infringement, as well as drug action, drug metabolism and drug adverse effects. His expertise includes drug patentability and patent infringement; pharmacology, psychopharmacology, toxicology and medicinal chemistry, as related to adverse drug reactions; DUI; performance enhancing drugs and “recreational drugs”; IV drug injury; steroids; retinoids; prostaglandins; ophthalmic drugs; and nucleosides.

Prior to that, as Cofounder and Senior Vice-President for Research and Development at ImmunoPharmaceuticals, Inc. in San Diego (now Pfizer) Dr. Wolff developed Thelin, an orally active, endothelin A receptor antagonist marketed in Europe for pulmonary arterial hypertension. Prior to that, Dr. Wolff was Vice-President for Research at Allergan, Inc. (then a Smith Kline subsidiary) in Irvine, CA where he developed four US marketed drugs: Alphagan, Combigan and Lumigan for glaucoma; and Tazorac for psoriasis. In earlier work for Smith, Kline and French in Philadelphia (now GSK) Dr. Wolff successfully synthesized aldosterone, carried out early studies on steroidal oral contraceptives, and developed the anabolic steroid SK&F 8048, which was registered and marketed in Canada.

Dr. Wolff was Professor and Chairman, Department of Pharmaceutical Chemistry, UCSF for twelve years (1966-1981). He is an elected Fellow of the American Association of Pharmaceutical Scientists, and an elected Fellow of the American Association for the Advancement of Science. He was on the faculty of the Drew University (NJ) Residential School of Medicinal Chemistry (1998-2008) where he annually lectured on drug discovery and pharmaceutical patents to more than 150 young researchers from the pharmaceutical industry. As a member of the USP Committee of Revision in Washington, DC (1990-2010), Dr. Wolff served on the Reference Standards Committee, which sets the legal standards for US drugs. He is the author of more than 90 scientific papers, 20 patents and the editor of several books. Dr. Wolff was the Assistant Editor of the Journal of Medicinal Chemistry, the premier Journal for Medicinal Chemistry, for four years (1968-1971). He has been a frequent contributor of book reviews for the Journal of Medicinal Chemistry and is a Registered Pharmacist and a Patent Agent registered to practice before the United States Patent and Trademark Office.